Summit Therapeutics SMMT United States — Long-Lived Assets
Discontinued — last reported Q3 '24
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NoncurrentAssets.
The official record: Summit Therapeutics’s 10-Q, filed October 30, 2024, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's united states — long-lived assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's united states — long-lived assets?
- Summit Therapeutics (SMMT) reported united states — long-lived assets of $7.58M in Q3 2024.
- How has Summit Therapeutics's united states — long-lived assets changed year-over-year?
- Summit Therapeutics's united states — long-lived assets increased by 30.7% year-over-year, from $5.8M to $7.58M.
- What does united states — long-lived assets mean?
- The total value of long-term assets held by the company within the United States.
- How do you interpret united states — long-lived assets?
- An increase suggests capital investment or expansion of operational capacity in the U.S. market, while a decrease may indicate asset divestiture, impairment, or a shift in strategic focus away from U.S.-based infrastructure.
- How does united states — long-lived assets compare across companies?
- Comparable to geographic property, plant, and equipment (PP&E) or non-current asset disclosures provided by other multinational biopharmaceutical firms.